# Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic

> **NCT01643278** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 29 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumor
- Stage III Soft Tissue Sarcoma
- Stage IV Soft Tissue Sarcoma

## Interventions

- **DRUG:** Dasatinib
- **BIOLOGICAL:** Ipilimumab
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01643278
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2017-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01643278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01643278, "Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01643278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*